At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $46.15M, above the global median of $18.58M
- FinancialsAltman Z-Score 3.53: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.54%Below 5Y avg (4.02%)
Annual Rate
CNY 0.38Paid annual
Payout Ratio
101.3%High
Payback Period
25.6 yr
Last Ex-Dividend
Oct 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.28BCNY791.63M · vs all stocks (USD)
Trailing P/E
14.70xRevenue (TTM)
3.73BCNY558.96M · vs all stocks (USD)
Profit Margin
9.10%Beta
0.2540xvs all stocks
52-Week Change
0.56%vs all stocks
Market Capitalization
5.28BCNY791.63M · vs all stocks (USD)
Enterprise Value
5.06BCNY757.80M · vs all stocks (USD)
Trailing P/E
14.70xPrice to Sales (TTM)
1.42xPrice to Book (MRQ)
1.75xEnterprise to Revenue
1.36xEnterprise to EBITDA
10.19xGross Margin
48.93%Profit Margin
9.10%Operating Margin
14.40%Return on Assets (TTM)
5.27%Return on Equity (TTM)
12.34%Revenue (TTM)
3.73BCNY558.96M · vs all stocks (USD)
Revenue per Share (TTM)
8.02CNYUpdated Oct 23, 2026Quarterly Revenue Growth
16.60%Gross Profit (TTM)
1.81BCNY271.67M · vs all stocks (USD)
EBITDA (TTM)
440.16MCNY65.98M · vs all stocks (USD)
Net Income (TTM)
339.41MCNY50.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
41.90%Operating Cash Flow (TTM)
577.78MCNY86.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
307.89MCNY46.15M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3800CNYUpdated Oct 23, 2026Trailing Annual Dividend Yield
3.54%vs all stocks
5-Year Average Dividend Yield
4.02%vs all stocks
Payout Ratio
101.26%Minority Interest (Equity)
321.86MCNYFY2025 · Dec 31, 2025Revenue
3.63BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.86BCNYFY2025 · Dec 31, 2025Gross Profit
1.77BCNYFY2025 · Dec 31, 2025Operating Income
377.75MCNY56.62M · vs all stocks (USD)
Pre-tax Income
435.10MCNYFY2025 · Dec 31, 2025Income Tax Expense
59.43MCNYFY2025 · Dec 31, 2025Net Income
375.67MCNYFY2025 · Dec 31, 2025EBIT
435.15MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
545.43MCNYFY2025 · Dec 31, 2025Research & Development
185.60MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
610.32MCNYFY2025 · Dec 31, 2025Other Operating Expenses
41.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
23.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
52.97KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6646CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6646CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
430.78MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
430.78MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
375.67MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-89.38MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
204.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
82.63MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
736.04MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
375.67MCNYFY2025 · Dec 31, 2025Other Non-cash Items
18.06MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-180.78MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-121.95MCNYFY2025 · Dec 31, 2025Purchase of Investments
-818.31MCNYFY2025 · Dec 31, 2025Sale of Investments
9.25MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-931.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-7.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-152.68MCNYFY2025 · Dec 31, 2025Other Financing Charges
23.45MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-136.23MCNYFY2025 · Dec 31, 2025Shares Outstanding
492.21MSharesUpdated Oct 23, 2026Float Shares
314.47MSharesUpdated Oct 23, 2026% Held by Insiders
40.87%vs all stocks
% Held by Institutions
5.37%vs all stocks
Total Cash (MRQ)
707.98MCNY106.12M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.44CNYUpdated Oct 23, 2026Total Debt (MRQ)
156.01MCNY23.38M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0466xCurrent Ratio (MRQ)
1.45xBook Value per Share (MRQ)
6.14CNYUpdated Oct 23, 2026Total Assets
4.96BCNY744.01M · vs all stocks (USD)
Total Current Assets
2.16BCNYFY2025 · Dec 31, 2025Total Liabilities
1.61BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.80BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
122.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.49BCNYFY2025 · Dec 31, 2025Cash
694.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
86.04MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
780.15MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.94MCNYFY2025 · Dec 31, 2025Accounts Receivable
284.85MCNYFY2025 · Dec 31, 2025Inventory
490.35MCNYFY2025 · Dec 31, 2025Accounts Payable
702.98MCNYFY2025 · Dec 31, 2025Short-term Debt
73.02MCNYFY2025 · Dec 31, 2025Other Current Liabilities
35.40MCNYFY2025 · Dec 31, 2025Long-term Debt
28.51MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.75MCNYFY2025 · Dec 31, 2025Common Stock (Book)
492.21MCNYFY2025 · Dec 31, 2025Retained Earnings
1.35BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.35BCNY502.16M · vs all stocks (USD)
52-Week Low
9.20CNYUpdated Oct 23, 202652-Week High
15.25CNYUpdated Oct 23, 202652-Week Change
0.56%vs all stocks
Beta
0.2540xvs all stocks
50-Day MA
11.89CNYUpdated Oct 23, 2026200-Day MA
10.75CNYUpdated Oct 23, 2026Avg 10-Day Volume
27.47MSharesUpdated Oct 23, 2026Avg 30-Day Volume
59.68MSharesUpdated Oct 23, 2026Diluted EPS (TTM)
0.7300CNYUpdated Oct 23, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 3.53: safe zoneNotable
Altman Z-Score: 3.53
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $46.15M, above the global median of $18.58MNotable
Levered free cash flow (USD): 46,150,118.943Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
InMode Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shouyao Holdings Beijing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Varex Imaging Corporation
Tier 1ProductionApproval-Gated PipelineRule
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule